Literature DB >> 32350693

Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms.

Valentina Andreasi1,2, Francesca Muffatti1, Giovanni Guarneri1, Massimo Falconi1,2, Stefano Partelli3,4.   

Abstract

OPINION STATEMENT: Pancreatic neuroendocrine neoplasms (PanNENs) are increasingly recognized entities, whose incidence has dramatically grown during the last two decades. Surgery plays a pivotal role in their management as it represents the only chance of cure. Since PanNENs display a wide range of aggressiveness, their surgical management needs to be tailored on tumor's and patient's characteristics. Currently, there are several open questions and burning issues in the field of PanNEN, such as the management of asymptomatic nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET) ≤ 2 cm. An active surveillance of these small lesions has been demonstrated to be safe although the available evidences are only based on retrospective studies. On the other hand, formal pancreatic resection associated with lymphadenectomy represents the gold standard for patients with localized NF-PanNEN > 2 cm or NF-PanNEN ≤ 2 cm in the presence of symptoms, dilation of the main pancreatic duct or suspicion of nodal metastases. Surgery plays also an important role in the setting of metastatic disease. In particular, surgery is generally recommended in the presence of low-grade, resectable, metastatic disease, but several series have reported also a survival benefit of palliative primary tumor resection in patients with unresectable liver metastases. The role of surgery in PanNEN G3 is still controversial. Indeed, surgery is associated with an improved survival in patients with well-differentiated PanNET G3, whereas there is almost no survival benefit in case of poorly differentiated lesions.

Entities:  

Keywords:  Lymphadenectomy; MEN-1 syndrome; Palliative resection; Pancreatic neuroendocrine neoplasms; Pancreatic neuroendocrine tumors; Surgery

Mesh:

Substances:

Year:  2020        PMID: 32350693     DOI: 10.1007/s11864-020-00736-w

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  6 in total

1.  Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.

Authors:  V Andreasi; C Ricci; R Casadei; M Falconi; S Partelli; G Guarneri; C Ingaldi; F Muffatti; S Crippa
Journal:  J Endocrinol Invest       Date:  2021-11-13       Impact factor: 4.256

2.  Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis.

Authors:  Zhen Yang; Jie Liang; Kaiming Leng; Guangjun Shi
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

3.  Grading Pancreatic Neuroendocrine Tumors via Endoscopic Ultrasound-guided Fine Needle Aspiration: A Multi-Institutional Study.

Authors:  Ammar A Javed; Alessandra Pulvirenti; Samrah Razi; Jian Zheng; Theodoros Michelakos; Yurie Sekigami; Elizabeth Thompson; David S Klimstra; Vikram Deshpande; Aatur D Singhi; Matthew J Weiss; Christopher L Wolfgang; John L Cameron; Alice C Wei; Amer H Zureikat; Cristina R Ferrone; Jin He
Journal:  Ann Surg       Date:  2022-01-25       Impact factor: 13.787

Review 4.  Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Qing-Yang Que; Lin-Cheng Zhang; Jia-Qi Bao; Sun-Bin Ling; Xiao Xu
Journal:  World J Gastrointest Surg       Date:  2022-05-27

5.  Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Juwan Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
Journal:  World J Gastrointest Oncol       Date:  2020-10-15

6.  Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasms.

Authors:  Mengfei Fu; Li Yu; Liu Yang; Yang Chen; Xiao Chen; Qinyu Hu; Hui Sun
Journal:  Front Nutr       Date:  2022-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.